Clinical Trial Update: The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetics study of 2% TD1414 cream in adults with secondarily infected traumatic lesions and impetigo has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impetigo
• Secondarily Infected Traumatic Lesions

Drugs mentioned

• TD1414 Cream

Snippet

Sponsor: LEO Pharma | Conditions: Secondarily Infected Traumatic Lesions (SITL), Impetigo | Phase 2 | Status: COMPLETED | Results posted: 2018-07-23